Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

[FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population].

Azagra R, Roca G, Martín-Sánchez JC, Casado E, Encabo G, Zwart M, Aguyé A, Díez-Pérez A; en representación del grupo de investigación GROIMAP.

Med Clin (Barc). 2015 Jan 6;144(1):1-8. doi: 10.1016/j.medcli.2013.11.014. Epub 2014 Jan 24. Spanish.

PMID:
24461732
2.

[Prediction of frailty fractures or prediction of densitometric osteoporosis. That is the question!].

Azagra R, López-Expósito F, Aguyé A, Encabo G; en representación del grupo GROIMAP.

Med Clin (Barc). 2013 Jul 7;141(1):43-4. doi: 10.1016/j.medcli.2012.11.031. Epub 2013 Mar 13. Spanish. No abstract available.

PMID:
23490485
3.

FRAX® tool, the WHO algorithm to predict osteoporotic fractures: the first analysis of its discriminative and predictive ability in the Spanish FRIDEX cohort.

Azagra R, Roca G, Encabo G, Aguyé A, Zwart M, Güell S, Puchol N, Gene E, Casado E, Sancho P, Solà S, Torán P, Iglesias M, Gisbert MC, López-Expósito F, Pujol-Salud J, Fernandez-Hermida Y, Puente A, Rosàs M, Bou V, Antón JJ, Lansdberg G, Martín-Sánchez JC, Díez-Pérez A, Prieto-Alhambra D.

BMC Musculoskelet Disord. 2012 Oct 22;13:204. doi: 10.1186/1471-2474-13-204.

4.

[New evidence on the discriminant and predictive capacity of the FRAX(®) tool in a Spanish female population].

Azagra R, Encabo G, Aguyé A, Iglesias M; en representación del grupo GROIMAP.

Aten Primaria. 2012 May;44(5):297-9. doi: 10.1016/j.aprim.2011.09.004. Epub 2011 Oct 21. Spanish. No abstract available.

5.

Measuring health-related quality of life in men with osteoporosis or osteoporotic fracture.

Zwart M, Azagra R, Encabo G, Aguye A, Roca G, Güell S, Puchol N, Gene E, López-Expósito F, Solà S, Ortiz S, Sancho P, Abado L, Iglesias M, Pujol-Salud J, Diez-Perez A.

BMC Public Health. 2011 Oct 9;11:775. doi: 10.1186/1471-2458-11-775.

6.

[Precautions required on using the predictive thresholds of the FRAX® tool to decide the need for an axial bone density scan in the Spanish population].

Azagra R, Zwart M, Aguyé A, Encabo G.

Aten Primaria. 2012 Mar;44(3):183-4. doi: 10.1016/j.aprim.2011.03.012. Epub 2011 Aug 19. Spanish. No abstract available.

7.

[Differences in the predictive values of the FRAX™ tool between the Spanish and United Kingdom population and considerations about the intervention threshold].

Azagra R, Roca G, Zwart M, Encabo G.

Med Clin (Barc). 2011 Dec 10;137(15):713-4. doi: 10.1016/j.medcli.2011.03.021. Epub 2011 May 23. Spanish. No abstract available.

PMID:
21601890
8.

Successful treatment for the Dunnigan-type familial partial lipodystrophy with Roux-en-Y gastric bypass.

Ciudin A, Baena-Fustegueras JA, Fort JM, Encabo G, Mesa J, Lecube A.

Clin Endocrinol (Oxf). 2011 Sep;75(3):403-4. doi: 10.1111/j.1365-2265.2011.04057.x. No abstract available.

PMID:
21521325
9.

Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain.

Azagra R, Roca G, Encabo G, Prieto D, Aguyé A, Zwart M, Güell S, Puchol N, Gene E, Casado E, Sancho P, Solà S, Torán P, Iglesias M, Sabaté V, López-Expósito F, Ortiz S, Fernandez Y, Diez-Perez A.

BMC Musculoskelet Disord. 2011 Jan 28;12:30. doi: 10.1186/1471-2474-12-30.

10.

33% radius evaluation to assess bone mineral density in prostate cancer patients.

Morote J, Planas J, Mir MC, Raventós CX, Encabo G, Doll A.

World J Urol. 2011 Dec;29(6):815-9. doi: 10.1007/s00345-010-0630-7. Epub 2010 Dec 30.

PMID:
21191598
11.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

PMID:
19549260
12.

Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child.

Soler Palacin P, Torrent A, Rossich R, Moraga FA, Yeste D, Carreño JC, Encabo G, Figueras C.

J Pediatr Endocrinol Metab. 2007 Aug;20(8):933-8.

PMID:
17937065
13.

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

Urology. 2007 Mar;69(3):500-4.

PMID:
17382153
14.

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J.

J Urol. 2006 May;175(5):1679-83; discussion 1683.

PMID:
16600728
15.

Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation.

Morote J, Trilla E, Esquena S, Abascal JM, Segura RM, Catalan R, Encabo G, Reventós J.

Int J Biol Markers. 2003 Oct-Dec;18(4):290-4.

PMID:
14756545
16.

Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment.

Morote J, Martinez E, Trilla E, Esquena S, Abascal JM, Encabo G, Reventós J.

Eur Urol. 2003 Dec;44(6):661-5.

PMID:
14644117
17.
18.

Prediction of prostate volume based on total and free serum prostate-specific antigen: is it reliable?

Morote J, Encabo G, López M, de Torres IM.

Eur Urol. 2000 Jul;38(1):91-5.

PMID:
10859448
19.

Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen.

Morote J, Lopez M, Encabo G, de Torres IM.

Eur Urol. 2000 May;37(5):537-40.

PMID:
10765091
20.

Effect of high-grade prostatic intraepithelial neoplasia on total and percent free serum prostatic-specific antigen.

Morote J, Raventós CX, Encabo G, López M, de Torres IM.

Eur Urol. 2000 Apr;37(4):456-9.

PMID:
10765077
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk